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Abstract
The human pyruvate dehydrogenase complex (PDHC) catalyzes the thiamine-dependent decarboxylation of pyruvate. Thiamine treatment
is very effective for some patients with PDHC deficiency. Among these patients, five mutations of the pyruvate dehydrogenase (E1)a subunit
have been reported previously: H44R, R88S, G89S, R263G, and V389fs. All five mutations are in a region outside the thiamine
pyrophosphate (TPP)-binding region of the E1a subunit. We report the biochemical and molecular analysis of two patients with clinically
thiamine-responsive lactic acidemia. The PDHC activity was assayed using two different concentrations of TPP. These two patients displayed
very low PDHC activity in the presence of a low (110 4 mM) TPP concentration, but their PDHC activity significantly increased at a
high (0.4 mM) TPP concentration. Therefore, the PDHC deficiency in these two patients was due to a decreased affinity of PDHC for TPP.
Treatment of both patients with thiamine resulted in a reduction in the serum lactate concentration and clinical improvement, suggesting that
these two patients have a thiamine-responsive PDHC deficiency. The DNA sequence of these two male patients’ X-linked E1a subunit
revealed a point mutation (F205L and L216F) within the TPP-binding region in exon 7.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
The human pyruvate dehydrogenase complex (PDHC)
catalyzes the thiamine-dependent decarboxylation of pyru-
vate, and plays an important role in energy metabolism of
the cell since it is an essential and rate-limiting enzyme
connecting glycolysis with the tricarboxylic acid cycle and
oxidative phosphorylation. Defects in PDHC are a common
cause of primary lactic acidemia. Clinical symptoms can
vary considerably in patients with PDHC deficiencies [1].
Thiamine treatment is very effective for some patients with
PDHC deficiency. The majority of PDHC deficiencies result
from mutations in the X-linked pyruvate dehydrogenase
(E1)a subunit gene [2,3]. The E1 component also contains
a thiamine pyrophosphate (TPP) binding site that is shared
by the a and h subunits [1,2]. In this study, we describe two
male patients with a point mutation (F205L and L216F)
within the TPP-binding region of the E1a subunit.
2. Materials and methods
2.1. Patients
2.1.1. Patient 1
A boy weighing 1464 g at birth was born at 34 weeks of
gestation. At 10 months of age, he suddenly developed
marked generalized muscle hypotonia and weakness, while
suffering from examthema subitum. He was admitted to the
hospital for evaluation. On admission, his blood lactate
concentrations ranged between 8.1 and 6.9 mM, and his
pyruvate concentrations between 1.1 and 0.76 mM with
lactate/pyruvate ratios between 7.4 and 9.2. The concen-
trations of lactate and pyruvate in the cerebrospinal fluid
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(CSF) were significantly elevated at 8.2 and 1.2 mM,
respectively. Amino acid analysis of his plasma showed
an elevated alanine concentration of 1497 Amol/l (normal
range, 320 to 480). He responded to 100 mg/day of thi-
amine. His blood lactate and pyruvate concentrations
decreased to 2.7 and 0.4 mM, respectively. After treatment
with a high dose of thiamine, the muscle weakness
improved, and he was able to walk. He no longer developed
generalized muscle hypotonia and weakness during febrile
illness, and his condition remained relatively stable at the
age of 2 years and 10 months. CT and MRI scans of the
patient’s brain showed no abnormalities.
2.1.2. Patient 2
The second patient was an 8-year-old boy, the second
child of healthy unrelated parents; his sister was healthy. He
was clinically normal at birth and during his first 2 years of
life. At 24 months, he developed an ataxic gait and muscle
weakness during a febrile illness, and he could not walk. He
was admitted to the hospital for evaluation. On admission,
his blood lactate (6.2 mM) to blood pyruvate (0.6 mM) ratio
was 10.3. The concentration of lactate and pyruvate in the
CSF were elevated at 5.1 and 0.64 mM, respectively. An
MRI of the brain showed a bilateral hypointense signal on
the T1 weighted images in the basal ganglia. He received 60
mg/day of thiamine. After the start of thiamine therapy, his
blood lactate and pyruvate concentrations decreased to the
normal range, and he was able to walk without support. His
muscle weakness and ataxia decreased and he did not
develop metabolic acidosis during febrile illnesses. The
abnormality on the brain MRI improved. He showed normal
development with only a slight gait disturbance after the age
of 6 years and was admitted to an elementary school.
2.2. Enzymatic assays
Lymphoblastoid cell lines derived from two patients with
clinically thiamine-responsive lactic acidemia were estab-
lished and cultured in RPMI 1640 medium (Nissui, Tokyo)
containing 3 10  3 mM thiamine-HCl as previously
described [4]. The activities of the PDHC and E1 in cultured
lymphoblastoid cells were assayed at two different concen-
trations of TPP (0.4 and 110 4 mM) [4]. The concen-
tration of TPP in normal human blood is 110 4 mM [5].
Protein concentrations were measured by the method of
Lowry et al. [6] with bovine serum albumin as a standard.
2.3. Assay of rate of [1-14C]pyruvate decarboxylation
The rate of [1-14C]pyruvate decarboxylation was meas-
ured by a modification of the method of Naito et al. [7].
Briefly, intact lymphoblastoid cells were harvested, washed,
and suspended with PBS. After preincubation with or with-
out thiamine-HCl (4 mM) for 60 min, the cells were
incubated in 0.2 ml of PBS containing 2.5 mM [1-14C]pyr-
uvate (0.1 mCi/mmol) in closed vessels at 37 jC for 30 min.
2.4. Molecular analysis of the PDHC-E1a gene
The great majority of PDHC deficiencies result from
mutations in the E1a subunit gene [3]. Mutation analysis of
the E1a gene was performed using genomic DNA from
cultured lymphoblastoid cells. For genetic analysis of the 11
exons of the E1a gene, individual exons of the gene were
amplified using primer pairs and conditions as described
previously [8]. These fragments, used to detect single-strand
conformation polymorphisms (SSCP), were sequenced
directly using appropriate amplification primers. SSCP
analysis was performed using the GeneGel Exel kit (Amer-
sham Pharmacia Biotech UK Ltd., Bucks, UK). Sequence
analysis was performed by an automated ABI 377 autose-
quencer using a dye-terminator kit (Applied Biosystems,
Norwalk, CT).
3. Statistical analysis
Statistical analysis of the biochemical data was per-
formed using Student’s t-test. A value of P < 0.05 was
accepted as statistically significant.
4. Results
4.1. Activities of PDHC
Two thiamine-responsive patients showed apparently low
activity of PDHC in the presence of low (110 4 mM)
TPP, as shown in Table 1, but their PDHC activities
significantly increased at a high (0.4 mM) TPP concentra-
tion. Most strikingly, the PDHC activity of patient 2
increased to within the normal range. The mother of patient
2 also had a low activity of PDHC under low TPP concen-
trations, but the PDHC activity was normal at a high TPP
concentration. Therefore, the PDHC deficiency in these two
patients and the mother of patient 2 was due to a decreased
affinity of PDHC for TPP.
Table 1
Activities of PDHC in cultured lymphoblastoid cells
PDHC (nmol/min/mg protein)a
With 110 4 mM TPP With 0.4 mM TPP
Patient 1 0.05F 0.02 * (4) 2.65F 0.38 * * (4)0
Patient 2 1.82F 0.11 * (4) 3.24F 0.33 (4)
Mother of Patient 2 2.34F 0.21 * (3) 4.34
Controls 3.99F 0.31 (6) 4.01F 0.66 (10)
PDHC: pyruvate dehydrogenase complex; TPP: thiamine pyrophosphate.
a DCA-activated PDHC values are the meansF S.D. of (n) determi-
nations or the result of a single determination.
* P< 0.001 vs. controls.
** P< 0.01 vs. controls.
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4.2. Affinity of PDHC for TPP
We investigated the affinities of normal and mutant
PDHC for TPP. As shown in Fig. 1, normal cells showed
approximately 50% of maximal PDHC activity in the
absence of TPP, and the addition of 110 5 mM TPP
restored full activity, with no further change in PDHC
activity at higher concentrations of TPP. However, cells
from the two thiamine-responsive patients showed signifi-
cantly lower PDHC activity at the 110 3 mM TPP
concentration. The addition of a high concentration (0.4
mM) of TPP restored activity to 66% and 81%, respectively,
of the maximal PDHC activity of normal cells.
4.3. Affinity of E1 for TPP
To investigate the affinity of E1 for TPP, we measured
the activities of DCA-activated E1 in the presence of 0.4 and
110 4 mM TPP (Table 2). There was no difference in
the E1 activity of normal controls in the presence of 0.4 and
110  4 mM TPP. In contrast, the activity of DCA-
activated E1 of the two patients was significantly lower in
the presence of 110 4 mM TPP, and the addition of a
high TPP concentration (0.4 mM) increased the average
activity to 36% and 64%, respectively, of the controls. Thus,
the E1 of these two patients also showed decreased affinity
for TPP.
4.4. Rate of [1-14C]pyruvate decarboxylation in intact
lymphoblastoid cells
During incubation without thiamine-HCl, intact lympho-
blastoid cells from the two patients with thiamine-respon-
sive PDHC deficiency showed decreased decarboxylation
rates of 25% and 22%, respectively, of the controls. How-
ever, during incubation with 4 mM thiamine-HCl, the
decarboxylation rate of these two patients increased mark-
edly to 45% and 49%, respectively, of the controls. In
contrast, the decarboxylation rate of the normal controls
scarcely increased (Table 3). Thus, pyruvate decarboxyla-
tion by intact lymphoblastoid cells from these two patients
were also thiamine-responsive.
4.5. Mutation analysis of the E1a subunit
DNA sequence analysis of the two patients’ X-linked
E1a subunit revealed a substitution within the TPP-binding
region in exon 7 of the E1a subunit. The genomic sequence
of patient 1 had a C!G point mutation at nucleotide 615,
resulting in the substitution of leucine for phenylalanine at
position 205 (F205L), and the genomic sequence of patient
2 had an A!C point mutation at nucleotide 648, resulting
in the substitution of phenylalanine for leucine at position
216 (L216F) as shown in Fig. 2. The genomic sequence of
the mother of patient 2 yielded A and C at nucleotide 648,
Fig. 1. Effect of TPP on the activity of DCA-activated PDHC in cultured
lymphoblastoid cells from normal subjects and two patients with thiamine-
responsive lactic acidemia. The activity of PDHC in cultured lympho-
blastoid cells is shown at various concentrations of TPP. o, normal
controls; ., patient 1; n, patient 2.
Table 2
Activities of E1 in cultured lymphoblastoid cells
E1 activity (nmol/h per mg protein)a
With 110 4 mM TPP With 0.4 mM TPP
Patient 1 0.23F 0.13 * (3) 1.41F 0.51 * * (3)
Patient 2 0.61F 0.27 * (3) 2.54F 0.30 (3)
Controls 3.17F 0.19 (5) 3.95F 1.06 (7)
E1: pyruvate dehydrogenase; TPP: thiamine pyrophosphate.
a DCA-activated E1 values are the meansF S.D. of (n) determinations
or the result of a single determination.
* P < 0.001 vs. controls.
* * P < 0.01 vs. controls.
Table 3
Rate of [1-14C]pyruvate decarboxylation in intact lymphoblastoid cells
Pyruvate decarboxylation (nmol/h/mg protein)
Without thiamine-HCl With thiamine-HCl
Patient 1 19.9F 6.3 * (4) 35.9F 5.3 * (4)
Patient 2 17.2F 4.0 * (3) 38.9F 5.2 * (4)
Controls 78.6F 7.2 (4) 80.0F 5.8 (3)
HCl: hydrochloride.
Values are the meansF S.D. of (n) determinations or the result of a single
determination.
* P < 0.001 vs. controls.
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resulting in a heterozygote for the L216F mutation (data not
shown).
5. Discussion
Defects in PDHC are an important cause of congenital
lactic acidemia in children. The great majority of PDHC
deficiencies result from mutations in the X-linked E1a
subunit gene [2,3]. The E1 subunit also contains a TPP
binding site that is shared by the a and h subunits [1,2].
Therefore, the E1a subunit plays an important role in the
thiamine-dependent decarboxylation of pyruvate. It has
been pointed out that the E1a subunit carries the TPP
binding motif GDG X26/27 NN common to all TPP-utiliz-
ing enzymes [1,9], and it is thought to be the region from
amino acid 195 in exon 6 to amino acid 225 in exon 7 [9].
Thiamine treatment is very effective for some patients with
PDHC deficiency. Among these patients with PDHC defi-
ciency responding to thiamine therapy, five mutations in the
E1a subunit gene have been reported previously: H44R,
R88S, G89S, R263G, and V389fs [4,10–12]. All five
mutations are in a region outside the TPP-binding site of
the E1a subunit. Recently, the roles of specific amino acid
residues in these two mutations (H44R and R263G) were
investigated using site-directed mutagenesis, and two muta-
tions had an increase in their apparent Km value for TPP
[13,14]. Therefore, thiamine responsiveness of these two
mutations is supported by a change in the Km value for TPP
observed in the recent study [13,14].
In this study, we described two clinically thiamine-
responsive male patients who had a point mutation
(F205L and L216F) within the TPP-binding region of the
E1a subunit. Unfortunately, it was not possible to analyze
the mother of patient 1 for the F205L mutation. We there-
fore do not know if this is a new or inherited mutation,
although this mutation had been identified previously in two
patients [15,16]. One patient was a male who died at age 18
months, with evidence of Leigh disease at autopsy [15].
Another male patient (patient 3929) was a 3-year-old child
with Leigh disease and psychomotor retardation [16]. Both
male patients showed evidence of Leigh disease and the
PDHC activities of these two patients were 25% and 36% of
the normal controls. The PDHC activities of our patient 1
were 1% and 66% of the normal controls at two different
concentrations of TPP as shown in Table 1. In male patients
with the same mutation (F205L), their cultured cells showed
quite different PDHC activity. These differences might have
been due to differences in the TPP concentration in these
assays of PDHC activity, or differences in the thiamine
concentration in the culture medium, or differences in the
cultured cells (skin fibroblasts and lymphoblastoid cells).
The concentration of thiamine-HCl in the culture medium
used for our studies was 3 10 3 mM, but there are
culture media with various concentrations of thiamine-HCl
ranging from 3 10 5 to 3 10 2 mM [11]. We pre-
viously reported that the PDHC activities of the patient with
thiamine-responsive PDHC deficiency (R263G mutation) in
the presence of 110 4 mM TPP was increased to about
two times by culturing cells in high-thiamine (0.4 mM)
medium [11]. Thus, it is possible that the PDHC activity in
the cultured cells with these thiamine-responsive mutations
might depend not only on the concentration of TPP in the
reaction mixture, but also on the concentration of thiamine
in the culture medium or within the cultured cells.
The L216F mutation of patient 2 is novel [3]. The L216F
mutation was inherited from his mother, because it was
found in the genomic DNA of his mother, and the PDHC
activity of his mother was significantly decreased in the
presence of low TPP concentration. We believe that the
F205L and L216F mutations were the cause of their disease:
aside from the presence of an appropriate defect in thiamine-
responsive PDHC and E1 activities, no other mutations
were found in the E1a subunit gene, and these two muta-
tions were not present in the genomic DNA from 50
unrelated controls. A comparison of the PDH E1a amino
acid sequence from a variety of different sources (pig heart,
rat liver, mouse liver, and yeast) shows that the amino acid
205 and 216 is phenylalanine and leucine, respectively [17–
20].
PDHC deficiency is generally diagnosed by measuring
the activity of PDHC in the presence of a high concentration
of TPP (0.1–0.7 mM) [11]. Two thiamine-responsive
Fig. 2. Amplified genomic fragments for the 11 exons of the E1a subunit
gene from two patients were sequenced and analyzed. (A) The genomic
sequence for exon 7 of patient 1 has a C!G point mutation at nucleotide
615, resulting in a substitution of leucine for phenylalanine at position 205
(F205L). (B) The genomic sequence for exon 7 of patient 2 has an A!C
point mutation at nucleotide 648, resulting in a substitution of phenyl-
alanine for leucine at position 216 (L216F).
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patients showed apparently low activity of PDHC in the
presence of low (110 4 mM) TPP, as shown in Table 1,
but their PDHC activities significantly increased at a high
(0.4 mM) TPP concentration. Most strikingly, the PDHC
activity of patient 2 increased to within the normal range.
Therefore, in order to diagnose this type of thiamine-
responsive PDHC deficiency and to prevent a diagnostic
error, it is important to measure the activity of PDHC in the
presence of a low (110 4 mM) as well as a high TPP
concentration.
Among the patients with PDHC deficiency caused by
mutations within the TPP-binding region, five mutations
have been reported previously: A199T, F205L, M210V,
W214R, and P217L [3,15,16,21–23]. Because the PDHC
activity in patients with these mutations was not measured
in the presence of low TPP concentrations, no one knows
whether or not these patients have thiamine-responsive
PDHC deficiency. These patients are all male, and all the
mutations except for the M210V mutation caused Leigh
disease. Therefore, it is possible that the PDHC deficiency
caused by mutations within the TPP-binding region might
lead to Leigh disease. However, our two patients had not
developed Leigh disease by the time of their diagnosis.
High-dose thiamine therapy might have been effective in
preventing Leigh disease in our patient. Recently, the roles
of two mutations (M210V and P217A) within the TPP-
binding region were investigated using site-directed muta-
genesis [24]. The apparent Km for M210V mutation
increased significantly, but P217A mutation did not affect
the apparent Km value for TPP. Thus, the different sub-
stitutions within the TPP-binding region can cause different
functional defects in the E1 enzyme.
No effective therapy for congenital lactic acidemia has
been established. In this study, the clinical symptoms in our
two patients were improved by high-dose thiamine therapy.
The clinical thiamine responsiveness in our patients was
confirmed by in vitro studies showing a thiamine-responsive
functional defect in the activities of PDHC and E1 in the
lymphoblastoid cells and the decarboxylation rate in intact
cultured lymphoblastoid cells. The DCA-activated PDHC
activity in the lymphoblastoid cells was maximal in the
presence of a high concentration of TPP. These data suggest
that the concomitant administration of a high dose of
thiamine and DCA may be required to achieve maximal
PDHC activity in patients with thiamine-responsive PDHC
deficiency, especially in patients with an acidotic crisis.
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